On 13 May 2003, Bortezomib (Velcade; Millenium) became the first proteasome inhibitor to be approved by the US FDA. Bortezomib was approved for multiple myeloma, a blood cancer that affects two to three people per 100,000, in record time — four months — on the basis of positive outcomes in early-phase trials.
Subscribe to Journal
Get full journal access for 1 year
only $22.08 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Coux, O., Tanaka, K. & Goldberg, A. L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 65, 801–847 (1996).
King, R. W., Deshaies, R. J., Peters, J. -M. & Kirschner, M. W. How proteolysis drives the cell cycle. Science 274, 1652–1659 (1996).
Kisslev, A. F. & Goldberg, A. L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 121, 1–20 (2001).
Hideshima, T. et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61, 3071–3076 (2001).
Barnes, P. J. & Karin, M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336, 1066–1071 (1997).
Palombella, V. J., Rando, O. J., Goldberg, A. L. & Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78, 773–785 (1994).
Adams, J. Proteasome inhibition in cancer: development of PS-341. Semin. Oncol. 28, 613–619 (2001).
Adams, J. et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 8, 333−338 (1998).
Anderson, P. G. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609–2617 (2003).
FDA Drug Approvals List [online] (cited 13 May 2003) <http://www.fda.gov/cder/foi/label/2003/021602lbl.pdf> (2003).
Zangari, M. et al. Marked activity also in Del 13 multiple myeloma (MM) of PS-341 (PS) and subsequent thalidomide (THAL) in a setting of resistance to post-autotransplant salvage therapies. Proc. Am. Soc. Hematol. A387 (2002).
Orlowski, R. Z. et al. Phase I study of the proteasome inhibitor bortezomib (PS-341, ValcadeTM) in combination with pegylated liposomal doxorubicin (DoxilTM) in patients with refractory hematological malignancies. Proc. Am. Soc. Hematol. A388 (2002).
About this article
A Sialylated-Bortezomib Prodrug Strategy Based on a Highly Expressed Selectin Target for the Treatment of Leukemia or Solid Tumors
Pharmaceutical Research (2019)
Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
British Journal of Cancer (2019)
Transcription-independent and -dependent p53-mediated apoptosis in response to genotoxic and non-genotoxic stress
Cell Death Discovery (2019)
Peptide Science (2019)
Cellular and Molecular Life Sciences (2019)